Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04805346 · ClinicalTrials.gov registry record · NA

Remote Ischemic Conditioning in Oncology

A NA study of Participants Undergoing Anthracycline Chemotherapy, sponsored by Children's Hospital Medical Center, Cincinnati.

Completed
Registry status
NA
Development phase
1
Enrollment target
1
Study location

NCT04805346 is a NA study of Participants Undergoing Anthracycline Chemotherapy that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04805346, a NA study of Participants Undergoing Anthracycline Chemotherapy, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.

COMPLETED
Registry status
NA
Development phase
1 participants
Enrollment target
1
Study location

Study Summary

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic conditioning (RIC) is feasible in children and young adults receiving anthracycline chemotherapy. The secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive RIC prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.

Interventions

  • DEVICE autoRIC®

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital - Cincinnati

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2021-04-30
Est. Completion 2024-05-03
Phase NA

What the Registry Record Tells You About NCT04805346

The ClinicalTrials.gov registry entry for NCT04805346 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Participants Undergoing Anthracycline Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which autoRIC® is the first listed.

NCT04805346 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04805346 about?

NCT04805346 is a clinical study titled "Remote Ischemic Conditioning in Oncology". This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study ...

What is the current status of trial NCT04805346?

This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2021-04-30. Estimated completion is 2024-05-03.

What conditions does trial NCT04805346 study?

This clinical trial studies the following conditions: Participants Undergoing Anthracycline Chemotherapy.

What interventions are being tested in trial NCT04805346?

The interventions under investigation include: autoRIC® (DEVICE).

Who is sponsoring clinical trial NCT04805346?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04805346 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.